Publication:
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells

Thumbnail Image

Date

2012

Journal Title

Journal ISSN

Volume Title

Publisher

Springer-Verlag
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Naito, Masayasu, Ursula Hainz, Ute E. Burkhardt, Buyin Fu, Deborah Ahove, Kristen E. Stevenson, Mohini Rajasagi, et al. 2012. Cd40l-tri, a novel formulation of recombinant human cd40l that effectively activates b cells. Cancer Immunology, Immunotherapy 62(2): 347-357.

Research Data

Abstract

CD40L has a well-established role in enhancing the immunostimulatory capacity of normal and malignant B cells, but a formulation suitable for clinical use has not been widely available. Like other TNF family members, in vivo and in vitro activity of CD40L requires a homotrimeric configuration, and growing evidence suggests that bioactivity depends on higher-order clustering of CD40. We generated a novel formulation of human recombinant CD40L (CD40L-Tri) in which the CD40L extracellular domain and a trimerization motif are connected by a long flexible peptide linker. We demonstrate that CD40L-Tri significantly expands normal CD19+ B cells by over 20- to 30-fold over 14 days and induces B cells to become highly immunostimulatory antigen-presenting cells (APCs). Consistent with these results, CD40L-Tri-activated B cells could effectively stimulate antigen-specific T responses (against the influenza M1 peptide) from normal volunteers. In addition, CD40L-Tri could induce malignant B cells to become effective APCs, such that tumor-directed immune responses could be probed. Together, our studies demonstrate the potent immune-stimulatory effects of CD40L-Tri on B cells that enable their expansion of antigen-specific human T cells. The potent bioactivity of CD40L-Tri is related to its ability to self-multimerize, which may be facilitated by its long peptide linker. Electronic supplementary material The online version of this article (doi:10.1007/s00262-012-1331-4) contains supplementary material, which is available to authorized users.

Description

Keywords

CD40, CD40L, B lymphocytes, Immunotherapy, Antigen-presenting cell

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories